Compare HELE & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HELE | AVIR |
|---|---|---|
| Founded | 1968 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 336.9M | 399.3M |
| IPO Year | 1996 | 2020 |
| Metric | HELE | AVIR |
|---|---|---|
| Price | $27.99 | $4.78 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $24.00 | $10.00 |
| AVG Volume (30 Days) | ★ 647.1K | 365.4K |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | ★ 1.51 | N/A |
| Revenue | ★ $1,478,845,000.00 | $351,367,000.00 |
| Revenue This Year | $1.78 | N/A |
| Revenue Next Year | $3.14 | N/A |
| P/E Ratio | $18.52 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.85 | $2.78 |
| 52 Week High | $30.68 | $6.45 |
| Indicator | HELE | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 53.96 | 53.40 |
| Support Level | $24.85 | $4.14 |
| Resistance Level | $30.51 | $5.04 |
| Average True Range (ATR) | 1.80 | 0.23 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 59.28 | 53.61 |
Helen Of Troy Ltd is a consumer products company offering creative products and solutions for its customers through a diversified portfolio of brands. It has two operating segments: Home and Outdoor segment provides a broad range of consumer products for home activities such as food preparation, cooking, cleaning, and organization; as well as products for outdoor and on-the-go activities such as hydration, food storage, backpacks, and travel gear, and The Beauty and Wellness segment provides beauty and wellness products including mass and prestige market beauty appliances, prestige market liquid-based hair and personal care products, and wellness devices including thermometers, water and air filtration systems, humidifiers, and fans.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.